Latest research on Duloxetine

Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company. Duloxetine has not yet been FDA approved for stress urinary incontinence or for fibromyalgia. Duloxetine is a selective SNRI (selective serotonin-norepinephrine reuptake inhibitor). Duloxetine is a systemic drug therapy which affects the body as a whole. Known also under the code name LY248686, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE- and 5-HT transporter sites. It is a less potent inhibitor of dopamine reuptake.

Duloxetine side effects

One hour following p.o. administration, Duloxetine increased withdrawal latency (Fig. 3A). [source, 2016]
Oxaliplatin‐treated macaques demonstrated a robust acute or early onset cold hypersensitivity as indicated by significantly decreased withdrawal latency to 10°C water, which was reversed by Duloxetine. [source, 2016]
Other adverse events occurring in ≥5% in both Duloxetine 60 and 40 mg groups were thirst, somnolence, headache, constipation, nasopharyngitis, diarrhea, decreased appetite, dizziness, anorexia, and malaise. [source, 2016]
Other behavioural and neuropsychiatric indications are more commonly managed with serotonin reuptake inhibitors (SSRIs, e.g. fluoxetine, Citalopram and Paroxetine) and serotonin-norepinephrine reuptake inhibitors (SNRIs, e.g., Duloxetine and Venlafaxine), and other drugs which increase central noradrenergic and serotonergic neurotransmission (e.g. Mirtazapine). [source, 2016]
Duloxetine was the drug that reported higher percentage of side effects (20.5%). [source, 2015]
It is believed that because Duloxetine has strong serotonin reuptake inhibition properties, it will be an effective treatment for OCD. [source, 2015]
This could have led to a placebo effect, increasing the response rate as subjects received increased doses of Duloxetine. [source, 2015]
On the other hand, there was a large and statistically significant increase in DESS total score from baseline to week 10 in the Duloxetine group (0.5 to 2.8, P<0.0001) after switching to placebo. [source, 2015]
For the Duloxetine and paroxetine groups, the mean (sd) decreases in baseline scores after 8 weeks of treatment were as follows: MADRS, 21.8 (7.8) versus 20.7 (8.6), t=1.02, p=0.311; HAMA, 12.5 (5.7) versus 12.2 (6.2), t=0.32, p=0.749; CGI-S, 2.49 (1.00) versus 2.34 (1.14), t=1.02, p=0.309; VAS-PI, 15.4 (18.6) versus 13.3 (19.0), t=0.83, p=0.407; SDS, 14.1 (6.5) versus 13.5 (7.1), t=0.65, p=0.515. [source, 2015]
The common side effects for Duloxetine reported in this study (nausea, dry mouth, constipation, loss of appetite, dizziness, diarrhea, drowsiness and fatigue) were similar to those reported in prior studies. [source, 2015]